Anton is a biomedical professional, scientist, innovator, entrepreneur and venture capitalist with 15 years of industry and academic experience in research and drug development. At ImmunoBiochem Corporation, Anton is leading the development of a new class of tumor microenvironment-targeted anti-cancer therapeutics. Anton was formerly the Director of Drug Development at Armour Therapeutics Inc., a biopharmaceutical company developing a new class of anti-cancer therapeutics for prostate, breast and ovarian cancers. Throughout his career, Anton worked on R&D and consulting projects with several biopharmaceutical companies developing biological therapeutics and immunotherapies in oncology. Anton has expertise in cancer research, immunology, chemistry, regenerative medicine and gene therapy, and authored more than 25 peer-reviewed publications and patents.
Anton obtained his PhD, MSc, and Hon. BSc degrees in medical biophysics, immunology, and biological chemistry at the University of Toronto, where he also completed postdoctoral work and his MBA at the Rotman School of Management. Anton is also a graduate of the CIHR Training Program in Regenerative Medicine (TPRM), Toronto General Hospital, University Health Network. Anton was a founding board member, and former CCO and organizing committee member of the Canadian Science Policy Centre (Toronto, ON) – a national organization promoting science policy in Canada.